In early 2025, ZiekenhuisNetwerk, a Dutch hospital group covering roughly a fifth of the country's non-academic hospitals, adjusted the reimbursement codes for 15 common surgical procedures. The new prices increased average surgical reimbursement by 23%. For most health insurers, the change was absorbed as a routine cost adjustment. But for Onderlinge Zorg, a midsize mutual with approximately 800,000 members, it triggered a cascade that within six months shrank its capital pool from roughly €1.2 billion to €1.05 billion—a 12.5% decline that brought its solvency ratio below its internal target. The episode, little noticed outside regulatory circles, has become a case study in a structural vulnerability that mutual insurers face in health lines: provider repricing risk.

One Hospital Group Repriced 15 Common Surgeries. A Mutual's Solvency Ratio Dropped.

ZiekenhuisNetwerk operates 14 hospitals and 22 outpatient clinics across the Netherlands, concentrated in the Randstad region. In January 2025, it notified insurers that it would reclassify several procedure codes—including knee arthroscopies, cataract removals, and hernia repairs—from lower-reimbursement categories to higher ones, reflecting what it argued were updated cost structures. The changes took effect in March 2025, with a three-month transition period.

For stock insurers like Achmea or CZ, the repricing added perhaps 1–2% to their annual claims expenditure—manageable within their larger capital bases and diversified portfolios. But for Onderlinge Zorg, which had a disproportionate share of its members concentrated in ZiekenhuisNetwerk's service area, the impact was outsized. The mutual's claims severity for those 15 procedures jumped roughly 25% year-over-year in the second quarter of 2025, according to internal data later shared with the Dutch central bank, De Nederlandsche Bank (DNB).

By mid-2025, Onderlinge Zorg's solvency ratio—the ratio of eligible own funds to solvency capital requirement—had fallen from an already modest 140% to 118%, below its internal target of 130%. DNB, which had been monitoring the mutual's capital position, issued a confidential letter in July 2025 requiring a remediation plan. The mutual responded by halting new member acquisitions in the affected region and renegotiating its reinsurance treaty mid-cycle—a rare and costly move.

The episode is not unique. In 2023, a similar repricing by a German hospital chain caused a smaller mutual's capital buffer to dip below regulatory thresholds, though the event was not publicly reported. What sets the Dutch case apart is the scale: a 12.5% capital erosion in six months from a single provider's pricing decision.

How a Single Repricing Cascades Into a Mutual's Balance Sheet

Mutual insurers operate on a simple principle: members pool premiums into a shared capital reserve, which is drawn down to pay claims. Unlike stock insurers, mutuals cannot issue equity to raise capital; they rely on retained earnings, member assessments, and, in some cases, subordinated debt. This structure works well when claims are predictable. But when a single external shock—a repricing, a regulatory change, a new treatment protocol—increases claim severity across a large block of business, the effect is concentrated on the mutual's capital.

In Onderlinge Zorg's case, the repricing did not increase claim frequency—members didn't suddenly have more surgeries. But each surgery cost more. The mutual's claims reserve had been set based on historical reimbursement levels. When those levels rose by 23%, the reserve proved inadequate. The mutual had to inject additional capital from its surplus, which was already thin.

Reinsurance treaties often exclude repricing risk. Standard excess-of-loss treaties cover large individual claims, not systematic increases in claim costs across a procedure group. Quota-share treaties might share the repricing impact, but they also share premium—and mutuals often retain more risk to keep premiums low. Onderlinge Zorg's treaty had a 70% retention on hospital claims, meaning it bore most of the repricing shock itself.

The mutual's board, in its 2025 annual report, noted that "the repricing event was not captured by our internal risk models, which assume stable provider pricing." That admission has spurred broader industry debate about whether mutuals need to model provider pricing volatility as a distinct risk factor, akin to catastrophe risk for property insurers.

The Structural Vulnerability: Mutuals vs. Stock Insurers in Health Lines

Stock insurers have several advantages in absorbing repricing shocks. They can raise capital by issuing new shares or debt, often within weeks. They can hedge repricing risk through derivatives—for example, by purchasing options on healthcare cost indices. And they can more easily adjust pricing across their entire book, since they are not constrained by membership governance.

Mutuals, by contrast, are limited in their ability to raise capital. They can impose member assessments—effectively a surcharge on premiums—but this is politically difficult and often capped by regulation. They can reduce benefits, but that risks member dissatisfaction and regulatory scrutiny. They can merge with another mutual, but this takes months and requires regulatory approval. In the meantime, capital erodes.

In the Netherlands, mutuals hold approximately 15% of the health insurance market by premium volume, according to DNB data as of late 2024. Most are small to midsize, serving regional or occupational groups. Their capital buffers are typically 100–150% of solvency capital requirements, compared to 180–250% for stock insurers. This thinner cushion makes them more vulnerable to shocks.

The vulnerability is not new, but it has been masked by years of low claims inflation and stable provider pricing. As healthcare costs rise and providers gain bargaining power—partly through consolidation—repricing events are becoming more common. A 2025 study by the Dutch Healthcare Authority found that hospital groups repriced an average of 12% of their procedure codes each year, with a median increase of 8%. For mutuals with concentrated exposure, such repricings can be material.

Regulatory Response: DNB's New Stress Test for Provider Pricing

In response to the Onderlinge Zorg episode and similar near-misses, DNB proposed in early 2026 a mandatory repricing stress scenario for all health insurers, with a focus on mutuals. The test, scheduled to take effect in 2027, requires insurers to simulate a 20% cost increase for the top-10 procedure groups by claims volume, and to demonstrate that their capital adequacy remains above 100% of the solvency capital requirement under that scenario.

For mutuals, the test is particularly stringent. They must also show that they have a plan to restore capital within six months if the scenario materializes—for example, through premium adjustments, benefit cuts, or reinsurance. Failure to meet the test triggers mandatory premium hikes or benefit reductions, as determined by DNB.

The proposal has drawn mixed reactions. Some mutual executives argue that a 20% increase is too severe and that the test would force them to hold more capital than necessary, raising premiums for members. Others welcome the clarity, saying it forces boards to take provider pricing risk seriously. "We've been flying blind on this," one mutual CEO told a Dutch insurance conference in May 2026. "A stress test gives us a framework to negotiate with hospitals."

DNB's approach mirrors similar moves by regulators in Germany and France, where mutuals also play a significant role in health insurance. The European Insurance and Occupational Pensions Authority (EIOPA) has issued a discussion paper on provider pricing risk, but has not yet proposed a harmonized stress test. The Dutch test could become a template.

What This Means for Policyholders: Premiums, Benefits, and Choice

For members of Onderlinge Zorg, the repricing has already had tangible consequences. In late 2025, the mutual announced a premium increase of 8% for 2026, citing the capital erosion and the need to rebuild reserves. It also reduced coverage for elective surgeries in its basic plan, increasing the deductible from €385 to €500 for those procedures. Members in the affected region face an additional co-pay of roughly €50 per surgery.

Other mutuals are watching closely. Some have begun renegotiating hospital contracts with repricing clauses that limit annual reimbursement increases to a healthcare cost index. Others are exploring pooled reinsurance arrangements that explicitly cover repricing risk—a market that is still nascent. A few smaller mutuals, with capital ratios below 110%, may consider merging with larger counterparts to gain scale and diversification.

Policyholders should check their mutual's solvency rating, which is published by DNB and by rating agencies such as AM Best. A rating below A- or a solvency ratio under 120% may indicate vulnerability to repricing shocks. Members should also review their plan's terms for benefit adjustments—some mutuals reserve the right to increase deductibles or co-pays if capital falls below a threshold.

The broader lesson is that mutual insurance, for all its member-friendly rhetoric, carries a structural risk that stock insurers can better absorb. Members trade potential dividend payments or premium rebates for the security of a mutual structure, but that security is only as strong as the mutual's capital buffer and its ability to manage provider pricing volatility.

Lessons for Industry: Rethinking Mutual Risk Management

The Onderlinge Zorg episode has prompted a rethinking of risk management in mutual health insurers. One clear lesson is that mutuals need repricing clauses in their hospital contracts—provisions that cap annual reimbursement increases or tie them to a publicly available health cost index. Such clauses are common in the United States, where insurers negotiate with hospital systems, but less so in the Netherlands, where pricing is more regulated.

Another lesson is that reinsurance should explicitly cover repricing risk. Standard treaties do not, but a bespoke layer—similar to an aggregate excess-of-loss treaty—could be designed to attach when a mutual's claims severity exceeds a threshold due to provider pricing changes. Some reinsurers, including Vantage Group, have shown interest in developing such products, though the market is small.

Capital requirements may also need mutual-specific adjustments. The current Solvency II framework treats repricing risk as part of underwriting risk, but does not require a separate stress scenario. DNB's proposal would fill that gap, but some argue that mutuals should be allowed to hold lower capital if they have strong contractual protections against repricing—a form of risk mitigation that the current framework does not fully recognize.

Finally, the episode highlights the potential for alternative risk transfer mechanisms. Analogue to catastrophe bond triggers, index-based repricing swaps could allow mutuals to hedge against a systemic increase in hospital reimbursement rates. The growth of insurance-linked securities (ILS) managers such as Fermat Capital, which recently surpassed $11 billion in ILS assets under management, suggests that investor appetite for non-catastrophe risk is growing. Whether repricing swaps become a viable asset class depends on the development of reliable indices and standardized contracts.

None of these solutions is a panacea. Repricing risk is inherently difficult to model because it depends on hospital pricing strategies, which are opaque and vary by region. Mutuals that operate in multiple regions with diversified provider networks are better positioned than those with concentrated exposure. But the underlying vulnerability—thin capital, no equity access, and exposure to provider pricing—is structural and unlikely to disappear.

Trade-offs and Counter-Arguments: Is Repricing Risk Overstated?

Not everyone agrees that repricing risk is a systemic threat to mutual insurers. Some analysts point out that the Onderlinge Zorg case, while dramatic, involved a mutual with unusually high exposure to a single hospital group. Most mutuals have more diversified provider networks, which dilutes the impact of any one repricing. For example, a mutual with members spread across multiple regions and dozens of hospital groups might see only a 1–2% capital impact from a similar event—within normal fluctuation.

Others argue that repricing risk can be managed through better contract design without new regulations. In the Netherlands, hospital contracts are typically renegotiated annually, and mutuals can push back against large increases by threatening to steer members to other providers. However, this leverage is limited in regions where a hospital group holds a near-monopoly. In such cases, mutuals may have no choice but to accept higher prices, as members cannot easily switch hospitals.

There is also a counter-argument that DNB's proposed stress test may be too conservative. A 20% increase across the top-10 procedure groups is a severe scenario that may not reflect typical repricing patterns. The Dutch Healthcare Authority's study found a median increase of 8%, and only a small fraction of procedure codes saw increases above 20%. Requiring mutuals to hold capital for an extreme scenario could lead to unnecessarily high premiums, which may drive members to lower-cost stock insurers or self-insurance arrangements.

Moreover, some mutual executives argue that the stress test ignores the mutual's ability to adjust premiums and benefits in response to repricing. In practice, mutuals can raise premiums within a regulatory band, typically up to 10% annually, without prior approval. This provides a buffer that the stress test does not fully capture. Critics say the test should allow for dynamic management actions rather than assuming a static capital position.

International Comparisons: Repricing Risk in Other Markets

The Dutch experience is not isolated. In Germany, mutual health insurers (Krankenversicherungsvereine) face similar challenges. A 2024 study by the German Insurance Association (GDV) found that hospital repricing events accounted for roughly 15% of solvency fluctuations among smaller mutuals. The German regulator, BaFin, has begun requiring mutuals to submit repricing sensitivity analyses, though it has not yet mandated a formal stress test.

In France, mutuals (mutuelles) dominate the health insurance market, covering about 75% of the population for supplementary health. French mutuals have historically been protected by regulated pricing, but recent reforms have allowed hospitals to negotiate prices more freely. A 2025 incident involving a Paris hospital group repricing oncology procedures caused a mid-sized mutual's solvency ratio to drop by 8 percentage points, prompting the French regulator (ACPR) to issue a warning. The mutual responded by renegotiating its reinsurance treaty to include a repricing layer, similar to what Dutch mutuals are now considering.

In the United Kingdom, mutual health insurers are less common, but the model exists in the form of "friendly societies." One such society, operating in the private healthcare market, experienced a repricing shock in 2024 when a major hospital chain increased prices for orthopedic procedures by roughly 15%. The society's capital buffer fell by 9%, leading to a merger with a larger mutual. The episode highlighted that repricing risk is not confined to the Netherlands and may grow as healthcare markets liberalize.

These international examples suggest that repricing risk is a structural feature of mutual health insurance, not a one-off anomaly. Regulators across Europe are watching the Dutch experiment closely. If DNB's stress test proves effective, it could become a benchmark for other jurisdictions. Conversely, if it leads to excessive capital requirements and market consolidation, it may deter mutual formation and reduce consumer choice.

Conclusion: Adapt or Shrink

The Dutch mutual sector will likely consolidate over the next few years, as smaller players struggle to meet the new capital requirements. Some may convert to stock insurers, though that is rare in the Netherlands. Others will seek partnerships with larger mutuals or with reinsurers. The outcome is uncertain, but one thing is clear: the era of stable provider pricing is over, and mutuals must adapt or shrink.

This article is for informational purposes only and does not constitute professional insurance or financial advice. Readers should consult a qualified advisor for decisions specific to their situation.